Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.

Ceriello A.

Diabetes Metab Res Rev. 2008 Jan-Feb;24(1):14-26. Review.

PMID:
17990280
2.

The anti-atherogenic effects of thiazolidinediones.

Stojanovska L, Honisett SY, Komesaroff PA.

Curr Diabetes Rev. 2007 Feb;3(1):67-74. Review.

PMID:
18220657
3.

Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.

Dandona P, Ghanim H, Chaudhuri A, Mohanty P.

J Diabetes Complications. 2008 Jan-Feb;22(1):62-75. doi: 10.1016/j.jdiacomp.2006.10.009. Review.

PMID:
18191079
4.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
5.

Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.

Roberts AW, Thomas A, Rees A, Evans M.

Curr Opin Lipidol. 2003 Dec;14(6):567-73. Review.

PMID:
14624133
6.

Vascular effects of TZDs: new implications.

Blaschke F, Spanheimer R, Khan M, Law RE.

Vascul Pharmacol. 2006 Jul;45(1):3-18. Epub 2006 Jun 5. Review.

PMID:
16740417
7.
9.
10.

Potential cardiovascular benefits of insulin sensitizers.

Kunhiraman BP, Jawa A, Fonseca VA.

Endocrinol Metab Clin North Am. 2005 Mar;34(1):117-35. Review.

PMID:
15752925
11.

The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis.

Murdolo G, Smith U.

Nutr Metab Cardiovasc Dis. 2006 Mar;16 Suppl 1:S35-8. Epub 2006 Feb 9. Review.

PMID:
16530128
12.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
13.

Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.

Schernthaner G.

Int J Clin Pract. 2009 Jun;63(6):912-29. doi: 10.1111/j.1742-1241.2009.02025.x. Review.

PMID:
19490202
14.

Pleiotropic effects of thiazolidinediones.

Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS.

Expert Opin Pharmacother. 2008 May;9(7):1087-108. doi: 10.1517/14656566.9.7.1087. Review.

PMID:
18422468
15.

Does reversal of oxidative stress and inflammation provide vascular protection?

Koh KK, Oh PC, Quon MJ.

Cardiovasc Res. 2009 Mar 1;81(4):649-59. doi: 10.1093/cvr/cvn354. Epub 2008 Dec 20. Review.

PMID:
19098298
16.

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

Doggrell SA.

Expert Opin Pharmacother. 2008 Feb;9(3):405-20. doi: 10.1517/14656566.9.3.405 . Review.

PMID:
18220491
17.

[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].

Bouskela E, Kraemer de Aguiar LG, Nivoit P, Bahia LR, Villela NR, Bottino DA.

Bull Acad Natl Med. 2007 Mar;191(3):475-92; discussion 492-3. French.

PMID:
18072649
18.

Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.

Fisher M.

Int J Clin Pract. 2009 Sep;63(9):1354-68. doi: 10.1111/j.1742-1241.2009.02150.x. Review.

PMID:
19691621
19.

Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.

Candido R, Zanetti M.

Ital Heart J. 2005 Sep;6(9):703-20. Review.

PMID:
16212072
20.

Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

Papanas N, Maltezos E.

Curr Pharm Des. 2009;15(27):3179-92. Review.

PMID:
19754390

Supplemental Content

Support Center